All-comers versus enrichment design strategy in phase II trials. - Wikidata - wikimedia - TriplyDB

All-comers versus enrichment design strategy in phase II trials.

All-comers versus enrichment design strategy in phase II trials.

http://www.wikidata.org/entity/Q34857268

about

Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review Design of clinical trials for biomarker research in oncology.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.A review of phase II trial designs for initial marker validation.Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials.

P2860

Q28086970-645FD2BD-7AFE-4E6E-BBC8-9D5CC22E72C3 Q35789708-48E75164-BCBE-44FB-81A5-601B9374B3A5 Q36507559-042C023E-F000-4387-B78F-A46A4355169E Q37188715-1BD24D82-2CE9-4A0C-88E0-6034BE5E0A2A Q37529483-01090312-9C84-4027-9C49-3CE111C783EA Q37731264-291B9A19-7C7B-4CBE-84F5-EBFCB99A4292 Q38450355-C3EBEFEC-075F-4E49-8D49-536C7F896A5D Q48257454-5671025D-19A3-49D1-B216-8C92A4BDFB56 Q53117937-D5877237-4A15-4C78-8787-4A3EB3F71F8D

P2860

All-comers versus enrichment design strategy in phase II trials.

http://www.wikidata.org/entity/Q34857268

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

All-comers versus enrichment design strategy in phase II trials.

@ast

All-comers versus enrichment design strategy in phase II trials.

@en

All-comers versus enrichment design strategy in phase II trials.

@nl

type

label

All-comers versus enrichment design strategy in phase II trials.

@ast

All-comers versus enrichment design strategy in phase II trials.

@en

All-comers versus enrichment design strategy in phase II trials.

@nl

prefLabel

All-comers versus enrichment design strategy in phase II trials.

@ast

All-comers versus enrichment design strategy in phase II trials.

@en

All-comers versus enrichment design strategy in phase II trials.

@nl

P1433

Q34857268-300C342F-EC12-4304-9E45-73D8F67A6701

P1476

Q34857268-9F858BC5-ADF2-4C15-9C6F-DA28195F890F

P2093

Q34857268-1906ABB9-2ACF-4C35-977A-56F700806CA5

Q34857268-1DC3CC84-85E6-47B5-BA88-41BDA0ADBBD5

P2860

Q34857268-2AED21FF-3B03-4838-BEFE-FD536596F695

Q34857268-40CE0E6C-A43C-4D23-BDAF-D5AEB77834AE

Q34857268-85F0C695-7C56-4FB4-9C29-00CD1A2ABED0

Q34857268-90F32C0F-4E35-4D06-962B-03983E6BDE66

Q34857268-A43ED1E0-9FAE-45E8-B1F9-2A0E852B70F1

Q34857268-A5BF9FF6-D25C-486C-A4FA-3864E6B8053B

Q34857268-B372A8B6-AAF4-4DC2-9648-A2B0D5B322EC

Q34857268-D20D1105-E75A-426D-B740-ABCB42514680

Q34857268-D73BF73C-3568-403D-AFA4-0347F0ADF2B8

P304

Q34857268-1A874356-B106-499F-9C67-2EE5E489354F

P31

Q34857268-0C2E5379-D179-4FB9-9C57-D3875FA8AB3D

P356

Q34857268-D244D5CE-D3DE-498D-B1AE-691713D1529C

P433

Q34857268-9EDF461A-CA82-4C59-9722-461EAF0BCF3A

P478

Q34857268-CB381711-76B3-40FD-AAE8-84C61CEF38AF

P577

Q34857268-14F3B5B0-510D-405B-B420-E22EB02E4507

P698

Q34857268-2160AA8F-EDBC-48B1-BF89-AE61E8E32380

P921

Q34857268-732B3EC8-6A3F-4206-AC30-14B185808BC3

P932

Q34857268-59FAB5EA-98A5-4B34-977B-16279C227B39

P356

JTO.0B013E31820E17CB

P1433

Journal of Thoracic Oncology

P1476

All-comers versus enrichment design strategy in phase II trials.

@en

P2093

Daniel J Sargent

http://www.w3.org/2001/XMLSchema#string

Sumithra J Mandrekar

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Randomized phase II trials: time for a new era in clinical trial design

Use of archived specimens in evaluation of prognostic and predictive biomarkers

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.

Crizotinib--latest champion in the cancer wars?

Equipoise lost: ethics, costs, and the regulation of cancer clinical research.

P304

658-660

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E31820E17CB

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21532916

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3082391

http://www.w3.org/2001/XMLSchema#string